Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader

About this update from Microbot Medical Inc.

Expanding manufacturing capabilities is part of the Company's cost reduction strategy and supports global expansion HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA) with Sanmina Corporation, a leading global integrated manufacturing solutions provider, to manufacture the LIBERTY System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. As momentum continues to rise in the U.S., reflected in increased accounts and usage across several states, and with the momentum building in the international markets as seen with the recent clearance in Israel and progress towards obtaining CE Mark as well as registration in additional markets, the Company believes it is necessary to expand its manufacturing capacity to meet expected demand from existing and new accounts as well as to support its cost reduction strategy. "We are pleased and excited to mark the signing of this agreement," said Asaf Shemesh, CEO, Sanmina Israel. "We are confident in the value of this partnership and what it represents for both organizations moving forward. We are eager and ready to support LIBERTY as it continues to grow and achieve its strategic objectives, while working together to ensure a successful and productive path forward." In addition to serving as a second site that diversifies the Company's manufacturing capabilities, the Company expects it will improve operating efficiencies, lower costs, and expand gross margins. Furthermore, as one of the largest contract manufacturers globally, Sanmina has sites across many regions which could be beneficial as the Company scales production to meet anticipated demand over the next couple of years. "As the pace of adoption continues to gain momentum, with several accounts across the Eastern U.S. increasing their utilization of the LIBERTY System and additional accounts in our existing and new sales territories are advancing in the sales funnel, we believe Sanmina will allow us to increase our manufacturing capacity and enable us to drive greater efficiency while addressing market demand for the foreseeable future," commented Michal Ahuvia, Director of Operations. "With plans to increase our sales footprint to the Western U.S....

View stock analysis, news, and events for Microbot Medical Inc.